News & Updates

Patients with maple syrup urine disease (MSUD) have lower levels of docosahexaenoic acid (DHA), resulting from inadequate dietary intake and change in n-3 polyunsaturated fatty acid (PUFA) metabolism, according to a study.

Type 2 diabetes (T2D) patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) concomitantly appear to be at lower risk of dementia compared with those receiving a GLP-1 RA or SGLT-2i monotherapy, according to a study.

Lipid parameters tend to get worse during the early remission phase following curative surgery for Cushing’s syndrome (CS), reveals a study.

An association exists between polygenic risk scores (PRS) and diabetes risk, irrespective of traditional risk factors, according to a study in Japanese general populations.

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.

In the treatment of patients with uncontrolled type 2 diabetes (T2D), adding empagliflozin to the combination of metformin plus evogliptin improves glycaemic control and other metabolic outcomes, as shown in a phase III study conducted in South Korea.